Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms

Blood Cells, Molecules & Diseases
Mariangela GrecoMaria Teresa Voso

Abstract

DNA methylation is one of the major epigenetic changes in human cancers, leading to silencing of tumor suppressor genes, with a pathogenetic role in tumor development and progression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Methylation of key promoter regions, induced by cytotoxic therapy together with complex genetic changes, is important in the biology of therapy-related myeloid neoplasms (t-MN). We were interested in the characterization of the methylation pattern of AML and MDS de novo and therapy-related. We studied 385 patients (179 females, 206 males), of a median age of 66 years (range 16-98 years). There were 105 MDS, 208 de novo AML and 72 t-MN (45 MDS and 27 AML). Using a methylation-specific PCR, we studied the promoter methylation status of E-cadherin (CDH1), TSP1 and DAP-Kinase 1. These genes have been shown to be involved in the malignant transformation, interfering with angiogenesis, interaction with micro-environment, apoptosis and xenobiotic detoxification. We found no associations between promoter hypermethylation and gender or age at the time of initial diagnosis. In patients with MDS, there were no associations between hypermethylation and clinical characteristics, including IPSS...Continue Reading

References

Feb 9, 2000·The Journal of Cell Biology·B M Gumbiner
Apr 21, 2001·Blood·M ToyotaJ P Issa
Mar 6, 2002·Blood·Jens Pedersen-BjergaardClaus Nerlov
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael S Gordon
Oct 21, 2004·American Journal of Hematology·Cumhur G EkmekciKishor Bhatia
Dec 2, 2004·Nature Reviews. Cancer·Jean-Pierre Issa
Oct 6, 2005·Biochemical and Biophysical Research Communications·Igor KoturbashOlga Kovalchuk
Feb 7, 2007·Cancer Research·Valentina BollatiAllen S Yang
Mar 30, 2007·Nature Genetics·Daniel Zilberman
Jun 10, 2008·Current Medicinal Chemistry·Giuseppe LeoneClara Nervi
Oct 7, 2008·The International Journal of Biochemistry & Cell Biology·Alexander Dobrovic, Lasse S Kristensen
Dec 25, 2008·Environmental and Molecular Mutagenesis·Yaroslav IlnytskyyOlga Kovalchuk

❮ Previous
Next ❯

Citations

Sep 16, 2011·Current Opinion in Oncology·Giuseppe LeoneMaria T Voso
Aug 3, 2012·Journal of Hematology & Oncology·Luana FianchiMaria Teresa Voso
Jul 22, 2011·Epigenetics & Chromatin·Tanja WaldmannRobert Schneider
Dec 1, 2011·Epigenomics·Nicole Engel, Andreas Rank
Feb 9, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Naser AmirizadehMahin Nikougoftar
Oct 31, 2009·Chemico-biological Interactions·Maria Teresa VosoGiuseppe Leone
Sep 16, 2011·International Journal of Cancer. Journal International Du Cancer·Rainer ClausChristoph Plass
Feb 22, 2011·British Journal of Haematology·Francesco D'AlòMaria Teresa Voso
Jun 16, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Ting-Juan ZhangJun Qian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.